Xov xwm

TSHIAB DELHI, Lub Rau Hli 22 (Xinhua) - Is Nrias teb tus kws tsim tshuaj tiv thaiv Bharat Biotech's Covaxin tau qhia txog 77.8 feem pua ​​​​kev ua tau zoo hauv theem III kev sim, ntau lub xov xwm hauv zos tau tshaj tawm hnub Tuesday.

"Bharat Biotech's Covaxin yog 77.8 feem pua ​​​​ntawm kev tiv thaiv COVID-19, raws li cov ntaub ntawv los ntawm theem III kev sim ua rau 25,800 tus neeg koom nrog thoob plaws Is Nrias teb," tsab ntawv ceeb toom tau hais.

Qhov kev ua tau zoo tau tshwm sim rau hnub Tuesday tom qab Drug Controller General ntawm Is Nrias teb (DCGI) pawg kws tshaj lij (SEC) tau ntsib thiab sib tham txog cov txiaj ntsig.

Lub tuam txhab kws tshuaj tau xa cov ntaub ntawv mus sim theem III rau cov tshuaj tiv thaiv rau DCGI lub lis piam.

Cov ntawv ceeb toom tau hais tias lub tuam txhab yuav tsum muaj "kev xa khoom ua ntej" lub rooj sib tham nrog World Health Organization cov tub ceev xwm hnub Wednesday, los tham txog cov lus qhia rau kev xa tawm zaum kawg ntawm cov ntaub ntawv xav tau thiab cov ntaub ntawv.

Is Nrias teb tau pib txhaj tshuaj tiv thaiv kab mob COVID-19 thaum Lub Ib Hlis 16 los ntawm kev tswj hwm ob qho tshuaj tiv thaiv hauv Is Nrias teb, uas yog Covishield thiab Covaxin.

Lub koom haum Serum ntawm Is Nrias teb (SII) yog tsim AstraZeneca-Oxford University's Covishield, thaum Bharat Biotech tau koom tes nrog Indian Council of Medical Research (ICMR) hauv kev tsim Covaxin.

Cov tshuaj tiv thaiv Sputnik V tau tsim los ntawm Lavxias kuj tau muab tso rau hauv lub tebchaws. Enditem